Impact of concurrent medications on outcomes with PD1/PD-L1 inhibitors for metastatic urothelial carcinoma.

被引：10
|
作者：
Agarwal, Archana
Pond, Gregory Russell
Curran, Catherine
Nassar, Amin
Nuzzo, Pier Vitale
Kumar, Vivek
McGregor, Bradley Alexander
Wei, Xiao X.
Harshman, Lauren Christine
Choueiri, Toni K.
Kilbridge, Kerry L.
Sonpavde, Guru
机构：
[1] St Elizabeths Med Ctr, Dana Farber Canc Inst, Brighton, MA USA
[2] McMaster Univ, Hamilton, ON, Canada
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[5] Dana Farber Canc Inst, Lank Ctr Genitourinary Malignancy, Boston, MA 02115 USA
[6] Dana Farber Canc Inst, Dept Genitourinary Oncol, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 07期
关键词：
D O I：
10.1200/JCO.2019.37.7_suppl.435
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
435
引用
收藏
页数：1
相关论文
共 50 条
  • [21] ANALYSIS OF PD1 AND PD-L1 EXPRESSION IN GLIOBLASTOMA
    Berghoff, A. S.
    Kiesel, B.
    Widhalm, G.
    Woehrer, A.
    Dieckmann, K.
    Filipits, M.
    Marosi, C.
    Hainfellner, J. A.
    Preusser, M.
    Wick, W.
    NEURO-ONCOLOGY, 2014, 16
  • [22] PD1 and PD-L1 expression in thymic lesions
    Bagir, E. Kilic
    Acikalin, A.
    Avci, A.
    Gumurdulu, D.
    Paydas, S.
    VIRCHOWS ARCHIV, 2017, 471 : S264 - S264
  • [23] Pretreatment Eosinophil Counts in Patients With Advanced or Metastatic Urothelial Carcinoma Treated With Anti-PD-1/PD-L1 Checkpoint Inhibitors
    Mota, Jose Mauricio
    Teo, Min Yuen
    Whiting, Karissa
    Li, Han A.
    Regazzi, Ashely M.
    Lee, Chung-Han
    Funt, Samuel A.
    Bajorin, Dean
    Ostrovnaya, Irina
    Iyer, Gopa
    Rosenberg, Jonathan E.
    JOURNAL OF IMMUNOTHERAPY, 2021, 44 (07) : 248 - 253
  • [24] PD-L1 Antibody Comparison in Urothelial Carcinoma
    Rijnders, Maud
    van der Veldt, Astrid A. M.
    Zuiverloon, Tahlita C. M.
    Grunberg, Katrien
    Thunnissen, Erik
    de Wit, Ronald
    van Leenders, Geert J. L. H.
    EUROPEAN UROLOGY, 2019, 75 (03) : 538 - 540
  • [25] Germinal immunogenetics predicts treatment outcome for PD1 PD-L1 checkpoint inhibitors
    Refae, Sadal
    Gal, Jocelyn
    Ebran, Nathalie
    Otto, Josiane
    Borchiellini, Delphine
    Peyrade, Frederic
    Chamorey, Emmanuel
    Brest, Patrick
    Milano, Gerard Alain
    Saada-Bouzid, Esma
    CANCER RESEARCH, 2019, 79 (13)
  • [26] Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors
    Hwang, Inhwan
    Park, Inkeun
    Yoon, Shin-kyo
    Lee, Jae Lyun
    CLINICAL GENITOURINARY CANCER, 2020, 18 (02) : E122 - E133
  • [27] Analysis of real-world PD-L1 testing in patients with urothelial carcinoma.
    Krigsfeld, Gabriel S.
    Prince, Emily
    Zerba, Kim
    Chizhevsky, Vladislav
    Ragheb, Josette William
    Novotny, James
    White, James William
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [28] Development of a diagnostic PD-L1 immunohistochemical assay for nivolumab therapy in urothelial carcinoma.
    Santos, Rose Ann de Los
    William, Josette
    Hanks, Debra Ann
    Northrup, Adam
    Jaiswal, Dipeshkumar
    Jansson, Malinka
    Phillips, Therese
    Cleveland, Rachel
    Satnick, Ilana
    Pierce, Coree
    Wynne, Bethany
    McDonald, Hendrick
    Carnahan, Josette
    Reddy, Swarnalatha Y.
    Phillips, Christine
    Brooks, Dania
    Inzunza, H. David
    Taylor, Clive R.
    Novotny, James
    Oroudjev, Emin
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [29] TARGETING PD1/PD-L1/PD-L2 SIGNALING IN ENDOMETRIOSIS
    Mamillapalli, Ramanaiah
    Golden, Adriana
    Taylor, Hugh S.
    Gawde, Nimisha
    FERTILITY AND STERILITY, 2023, 120 (04) : E307 - E307
  • [30] Evaluation of PD-L1 biomarker for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatments for urothelial carcinoma patients: A meta-analysis
    Rui, Xin
    Gu, Ting-Ting
    Pan, Hua-Feng
    Zhang, Hui-Zhi
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2019, 67 : 378 - 385
12345